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Objectives: percutaneous transluminal angioplasty with stenting is perceived to be a less invasive and cheaper option
for the treatment of iliac artery occlusion than surgical reconstruction. We have carried out a prospective observational
study of all patients undergoing an iliac stent or femorofemoral crossover graft for iliac artery occlusion to assess the
cost effectiveness of the two approaches in a district general hospital.
Methods: fifty-one patients underwent primary angioplasty with stenting and 87 patients crossover grafting. Patients
were all assessed 2 months after their procedure and then at intervals over the following years.
Results: in 13 cases, it was impossible to place the stent successfully. In a further 10 patients, major complications
occurred which were mainly thromboembolic. Fifteen patients underwent crossover grafting after failure to insert a stent,
or after stent occlusion. No major complications occurred following crossover grafting. The median length of stay following
successful stenting was 1 day; the following crossover grafting was 4 days. The mean stay was higher in each group (2.5
and 5.8 days) and is a more accurate parameter for estimation of cost, which for iliac stenting is estimated at £1912
versus £3072 for crossover grafting. The mean additional cost of those patients sustaining complications after stenting
was £2481. On an ‘‘intention to treat’’ basis, patency following stent insertion at 6 months was 52%; patency after
bypass was 100% (p<0.0001). If any complication occurs after stenting, the cost advantage of the procedure is lost. In
those patients without complication, the initial cost benefit of iliac stenting is lost within 6 months, as patients require
further intervention, usually as a crossover graft, when the stent occludes. Crossover grafting is a durable low-risk
procedure.
Conclusions: we suggest that stenting of occluded iliac arteries should be reserved for those patients with limited life
expectancy. Patients who are younger and fitter should be offered femorofemoral crossover grafting as a primary procedure
until research enables identification of those patients who are most likely to maintain long-term patency after stenting.
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Introduction shorter hospital stay is reflected in the long-term costs
of the procedure.
In recent years there has been a trend away from
aortofemoral bypass grafting towards less invasive
procedures in the treatment of aortoiliac occlusive Materials and Methods
disease. From 1988 to 1994, we found that extra-
anatomic bypass grafts (mainly femorofemoral cross- One hundred and thirty-eight patients presenting to
over) were being used in preference to aortofemoral the Royal Berkshire Hospital between January 1993
bypass.1 However, from 1994 to 1996, the number and December 1997 with iliac occlusion underwent a
of crossover grafts declined with increasing use of full clinical assessment including ankle–brachial pres-
percutaneous transluminal angioplasty with stents.1 sure index (ABPI) and intravenous digital subtraction
The aim of this study was to examine the relative angiography (IVDSA). Where there was evidence of a
merits of iliac stenting and femorofemoral crossover unilateral iliac artery occlusion which would have
grafts for iliac occlusions. In particular, we sought to been treated with femorofemoral crossover grafting,
determine whether the perceived ease of stenting and consideration was given to percutaneous angioplasty
(PTA) with stenting of the lesion. Patients with iliac
stenosis alone are not included in this study. In the
∗ Please address all correspondence to: P. J. Whatling, Nuffield early patients femorofemoral crossover grafting wasDepartment of Surgery, Level 6, John Radcliffe Hospital, Oxford
OX3 9DU, U.K. the treatment of choice, but, as stenting increased in
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Table 1. Case distribution by year. pulse and ABPI. Duplex scanning or IVDSA was car-
ried out if clarification of clinical findings was needed.Crossover graft Stent
Analysis of patency in each group was performed
1993 20 2 using the method described by Kaplan and Meier.2
1994 26 14 Statistical analysis was with the Breslow–1995 16 11
1996 13 14 Gehan–Wilcoxon test (a rank test, which gives greater
1997 12 10 weight to time points with more observations in the
risk set) and performed using StatView (SAS Inc.,
Carey, NC, U.S.A.).Table 2. Demographic data.
Each inpatient episode was broken down into vari-
Crossover graft Stent ous components to give an estimate of cost (Table
3). We did not include the costs of pre-interventionNumber of patients 87.00 51.00
Male:female ratio 2.52 1.55 radiology, nor of outpatient follow-up, since these are
Mean age/years (s.d.) 67.9 (10.5) 61.9 (10.1) the same for both groups.Age range/years 48–88 46–85
Resultspopularity, greater numbers of patients were stented
(Table 1). This was an observational study and patients
There were no major perioperative complications inwere not randomised. Patients in whom PTA failed
the 87 patients who had crossover grafts. Four patientswere offered femorofemoral crossover grafting. All
sustained cutaneous bruising and wound discomfortcases were assessed as having adequate proximal in-
and one patient developed urinary retention. Oneflow and distal run-off vessels, but we made no attempt
patient developed short-distance claudication after 1to stratify the patients according to the run-off vessel
year and required a below-knee femoropopliteal graft.status.
This occluded after a further 10 months. ArteriographyDemographic data are presented in Table 2. The
confirmed that the crossover graft was patent into themajority of patients had short-distance intermittent
profunda artery, but the graft occluded 2 months later.claudication (121), the remainder, ischaemic rest pain
Fifty-one patients underwent PTA and stent in-(10) and ulcers (seven). Fourteen patients were dia-
sertion, one patient requiring three stents, two patientsbetic. Half of the occlusions involved the common iliac
two stents and the remainder one stent. There wereartery, with half of these also involving the external
13 unsuccessful attempts, 12 due to a failure to crossiliac artery; the remainder were confined to the external
the occlusion with the guidewire, and one due toiliac artery.
inadequate angioplasty. Nine failures occurred in thePTA and stenting was performed under local
first 21 cases and subsequently one in every 10 casesanaesthetic using standard techniques. The occlusion
attempted. Eleven of these patients required femo-was approached from the ipsilateral common femoral
rofemoral crossover grafting and one an aorto-artery, crossed with a guidewire and angioplasty per-
bifemoral graft. In addition, complications occurred informed using an appropriately sized balloon. Once
10 patients successfully stented. Four patients requiredflow was re-established, a self-expanding Wallstent
femoral embolectomy shortly after stent placement(Schneider Europe, Zurich, Switzerland) was inserted.
and one patient developed a brachial embolus, pre-Diameter of stent used ranged from 6–12 mm (median
sumably from the arteriogram catheter being advanced8 mm). Patency was confirmed with two-plane angio-
into the aortic arch. In two patients the stent occludedgraphy. Patients not already taking aspirin were pre-
immediately after the procedure – one underwentscribed a daily dose of 75 mg.
successful thrombolysis. Two patients occluded theirFemorofemoral crossover grafting was performed
stents within two weeks of insertion and thrombolysisunder general anaesthesia. In all cases, an 8-mm col-
failed. One patient developed a saccular false an-lagen-coated knitted Dacron graft (Vascutek Gelsoft,
eurysm at the proximal end of the stent in the commonSulzer Medica, Renfrewshire, Scotland (U.K.)) was
iliac artery 6 months after stent insertion and under-tunnelled subcutaneously across the lower abdominal
went an aortofemoral graft.wall and anastomosed to each common femoral artery
with a continuous 4/0 polypropylene suture.
Graft or stent patency was assessed in all patients Patency
2 months after the procedure and then at least annually
thereafter. Assessment was clinical, based on symp- Patency figures are calculated to the last confirmed
date of patency and are shown in Figures 1 and 2.tomatology and the presence of a palpable femoral
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Table 3. Breakdown of costs.
Crossover graft Stent
Device cost £430 £1030
(including insertion devices, packs, sterile drapes, drugs and contrast)
Theatre or angiogram suite cost £500 £140
(hourly rate including all staff costs and anaesthetic/recovery time)
Mean duration of procedure 1.5 hours 1 hour
Overnight stay £330 £330
Cost analysis
These results have been analysed on an intention-to-
treat basis. Mean total procedure cost for crossover
grafting was £3072, whereas that for stenting was £1912
(a reduction of 62%) with the principal determinant of
cost being length of stay (Table 4).
The aim of this study was to examine the costs of
the standard management as practised in a vascular
unit. Analysis of costs, which are distributed as con-
tinuous data, would typically be based upon a median
value for length of stay and procedure cost, with the
interquartile range given as a measure of variability.3
The inherent positive skew in data regarding length
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of stay invariably leads to an underestimation of theFig. 1. Patency (numbers at risk). (——) Crossover grafts; (––––)
true procedure cost when using the median.4 There-stents (after successful placement); (–––––) stents (intention to treat).
fore, whilst we have reported the median and in-
terquartile ranges for length of stay (this variable being
the primary determinant of an increased cost for a
given patient), our conclusions are based on the arith-
metic mean of the costs incurred by each individual
patient.
At first glance, stenting has a significant cost ad-
vantage over crossover grafting. However, the mean
additional cost of those patients requiring crossover
grafting after failure of stent was £2481 (s.e.m. £191).
The cost advantage is lost when 48% of stents are
occluded (Fig. 2), which in our study is within 6
months of the procedure. It is important to track costs
for an adequate period of time after an event,5 in this
case for many months beyond the time where patency
rates diverge (Fig. 1).
0
4000
Percentage of stents failing (assumes 100%
cross-over patency in this range)
M
ea
n
 c
os
t 
pe
r 
pa
ti
en
t 
(£
)
0
500
1000
1500
2000
605040302010
2500
3000
3500
Point at which stents are no longer
cost effective
Fig. 2. The cost of stent failure (intention to treat). (––––) Crossover
grafts; (––––) stents.
Discussion
Much of the published literature only examines pat-With only one graft occlusion at 24 months, crossover
grafting is confirmed to be a durable procedure. ency rates after stenting and does not consider those
patients in whom stenting is attempted but fails. OurStented arteries suffer a rapid fall in patency over the
first 6 months to 78% (secondary) declining to 68% at results, when analysed in this way, are comparable to
those published elsewhere;6 this confirms the validity4 years. Intention to treat 6-month patency is lower at
52%. of our study as a representative sample of patients.
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Table 4. Calculated costs of each procedure.∗
Crossover graft Stent
Median (IQR) Mean (s.e.m.) Median (IQR) Mean (s.e.m.)
Stay length/days 4 (3) 5.8 (0.6) 1 (0) 2.5 (0.6)
Total cost of procedure/£ sterling 2500 (990) 3072 (201) 1500 (0) 1912 (215)
∗ This includes the cost of an inflow procedure such as angioplasty and/or stenting in five patients.
Our data suggest that there is a case for femoro- infection,17 but one patient developed a false aneurysm
at the site of the stent, which has been reported pre-femoral crossover grafting in preference to angioplasty
with stenting for unilateral iliac artery occlusion. This viously.18,19 These complications are likely to become
more evident with the increasing use of such deviceswas not a randomised study and the numbers of
patients are relatively small. A closer examination of and will increase the complexity and risks of sub-
sequent management of the patient as well as addingthe data reveals that there are a number of areas
that warrant further investigation before a definitive to the overall costs of care.
Other studies have examined the relationship be-statement can be made.
We elected to stent all occlusions that had undergone tween stent patency and the status of the distal vas-
culature.20,21 We have no doubt that distal vesselsuccessful angioplasty. Since the first angioplasty of
an occluded iliac artery in 1979,7 workers have sought patency will contribute to long-term patency of iliac
stents or crossover grafts. Our sample sizes are tooto improve the short- and long-term patency of this
procedure. Development of expandable metal stents8 small to analyse the effects of distal stenosis or oc-
clusion on patency.and their use in iliac arteries appeared to offer a
substantial improvement over angioplasty alone.9 This Vetto first reported crossover grafting nearly 40 years
ago.22 Considerable experience has been gained withis thought to result from a reduction in the effects of
elastic recoil after angioplasty, even though neo-intima the operation, which has been shown to be an effective
and durable procedure with a low complicationformation is enhanced in arteries stented after an-
gioplasty.10 A recent meta-analysis of the major studies rate,23 most commonly being local complications such
as haematoma and local wound infection.24 Early graftof angiopasty and stenting, reported over the last few
years, shows that only 23% of lesions were occlusions, infection occurs in less than 1% of patients where
collagen coated grafts are used.25the remainder being stenoses.6 However, there is a 5%
improvement in the immediate technical success rate Our results demonstrate clearly that, with current
patency rates, stenting of iliac arteries is not as cost-and a 7–11% improvement in 4-year primary patency
rate with stenting after angioplasty compared to an- effective as femorofemoral crossover grafting in uni-
lateral iliac artery disease. Cost is not the sole factorgioplasty alone. Our decision to stent all patients was
based on early reports where stents were used as a to be considered when assessing the benefits of a
procedure. Patient comfort and well-being are alsoprimary adjunct to angioplasty.9,11,12 More recent
work13,14 has shown that restricting stent insertion to important, with the advantages of a shorter stay and
absence of a surgical wound as the most pertinentcomplex cases, or where there is a significant pressure
gradient after angioplasty (>10 mmHg), does not result factors. Clearly, there is a balance of a less invasive
procedure on the one hand, against a better long-termin any decrease in patency at 24 months, which, at
76%, is identical to that in our study. patency on the other.
Although we have demonstrated that patency fallsDetermination of the success of angioplasty with
angiographic views in two planes is known to have a rapidly within the first 6 months, we have also dem-
onstrated that nearly half our patients can expect long-sensitivity and specificity of around 70% for critical
stenoses.15 However, in our study all lesions were term stent patency. In our study, the rapid fall in
patency leaves a small number of patients who arestented and this failing is of less relevance compared
with a study where stenting was selective. The decision followed up long-term, potentially skewing the results,
although our statistical analysis adds a reducedto stent based upon a gradient of 10 mmHg is possibly
no more valid scientifically than the observational weighting to this group. Stents are a routine part of
the management of iliac occlusive disease and futureassessment of a skilled radiologist, given the overall
lack of understanding of the correlation of vessel research needs to be directed at determining which
groups of patients will maintain stent patency in themorphology with intraluminal pressure.16
We were fortunate that no patient developed stent long term and which would be better served with
Eur J Vasc Endovasc Surg Vol 20, July 2000
P. J. Whatling et al.40
modality in aorto-iliac occlusive disease. Am J Surg 1994; 168:surgical intervention. There is evidence that factors
202–204.such as the state of the distal vasculature will make a 13 Treiman GS, Schneider PA, Lawrence PF et al. Does stent
placement improve the results of ineffective or complicated iliacdifference to patency, as will cigarette smoking and
artery angioplasty? J Vasc Surg 1998; 28: 104–112; discussiondiabetes. Until there are prospective multicentred stud-
113–114.ies examining these issues, we are not best serving 14 Tetteroo E, van der Graaf Y, Bosch JL et al. Randomised
comparison of primary stent placement versus primary an-our patients, either in terms of treatment method or
gioplasty followed by selective stent placement in patients withresource usage.
iliac-artery occlusive disease. Dutch Iliac Stent Trial Study Group.
Lancet 1998; 351: 1153–1159.
15 Thiele BL, Strandness DEJ. Accuracy of angiographic quan-
tification of peripheral atherosclerosis. Prog Cardiovasc Dis 1983;
References 26: 223–236.
16 Bonn J. Percutaneous vascular intervention: value of hemo-
dynamic measurements [editorial; comment]. Radiology 1996;1 Toogood GJ, Torrie EP, Magee TR, Galland RB. Early ex-
201: 18–20.perience with stenting for iliac occlusive disease. Eur J Vasc
17 Chalmers N, Eadington DW, Gandanhamo D, Gillespie IN,Endovasc Surg 1998; 15: 165–168.
Ruckley CV. Case report: infected false aneurysm at the site of2 Kaplan EL, Meier P. Nonparametric observation from in-
an iliac stent. Br J Radiol 1993; 66: 946–948.complete observations. J Am Statist Assoc 1958; 53: 457–486.
18 Thibodeaux LC, James KV, Lohr JM, Welling RE, Roberts3 Altman DG, Gore SM, Gardner MJ, Pocock SJ. Statistical
WH. Infection of endovascular stents in a swine model. Am Jguidelines for contributors to medical journals. BMJ 1983; 286:
Surg 1996; 172: 151–154.1489–1493.
19 Hearn AT, James KV, Lohr JM et al. Endovascular stent infection4 Barber JA, Thompson SG. Analysis and interpretation of cost
with delayed bacterial challenge. Am J Surg 1997; 174: 157–159.data in randomised controlled trials: review of published studies.
20 Sullivan TM, Childs MB, Bacharach JM, Gray BH, Pied-BMJ 1998; 317: 1195–1200.
monte MR. Percutaneous transluminal angioplasty and primary5 Drummond MF, O’Brien B, Stoddart G, Torrance GW.
stenting of the iliac arteries in 288 patients. J Vasc Surg 1997; 25:Methods for the Economic Evaluation of Health Care Programmes.
829–838; discussion 838–839.Second ed. Oxford: OUP; 1997.
21 Ballard JL, Bergan JJ, Singh P, Yonemoto H, Killeen JD.6 Bosch JL, Hunink MG. Meta-analysis of the results of per-
Aortoiliac stent deployment versus surgical reconstruction: ana-cutaneous transluminal angioplasty and stent placement for
lysis of outcome and cost [see comments]. J Vasc Surg 1998; 28:aortoiliac occlusive disease (published erratum appears in Ra-
94–101; discussion 101–103.diology 1997; 205: 584). Radiology 1997; 204: 87–96.
22 Vetto RM. The treatment of unilateral iliac artery obstruction7 Tegtmeyer CJ, Moore TS, Chandler JG, Wellons HA, Rudolf
with a transabdominal subcutaneous femorofemoral graft. Sur-LE. Percutaneous transluminal dilatation of a complete block in
gery 1962; 52: 542–545.the right iliac artery. AJR 1979; 133: 532–535.
23 Perler BA, Williams GM. Does donor iliac artery percutaneous8 Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L.
transluminal angioplasty or stent placement influence the resultsIntravascular stents to prevent occlusion and restenosis after
of femorofemoral bypass? Analysis of 70 consecutive cases withtransluminal angioplasty. N Engl J Med 1987; 316: 701–706.
long-term follow-up. J Vasc Surg 1996; 24: 363–369; discussion9 Palmaz JC, Richter GM, Noeldge G et al. Intraluminal stents
369–370.in atherosclerotic iliac artery stenosis: preliminary report of a
24 Berce M, Sayers RD, Miller JH. Femorofemoral crossovermulticenter study. Radiology 1988; 168: 727–731.
grafts for claudication: a safe and reliable procedure. Eur J Vasc10 Hehrlein C, Zimmermann M, Pill J et al. The role of elastic
Endovasc Surg 1996; 12: 437–441.recoil after balloon angioplasty of rabbit arteries and its pre-
25 Braithwaite BD, Davies B, Heather BP, Earnshaw JJ. Earlyvention by stent implantation. Eur Heart J 1994; 15: 277–280.
results of a randomized trial of rifampicin-bonded Dacron grafts11 Vorwerk D, Guenther RW. Mechanical revascularization of
for extra-anatomic vascular reconstruction. Joint Vascular Re-occluded iliac arteries with use of self-expandable endo-
search Group. Br J Surg 1998; 85: 1378–1381.prostheses. Radiology 1990; 175: 411–415.
12 Williams JB, Watts PW, Nguyen VA, Peterson CL. Balloon
angioplasty with intraluminal stenting as the initial treatment Accepted 14 February 2000
Eur J Vasc Endovasc Surg Vol 20, July 2000
